Model SENTI-202 - Acute Myeloid Leukemia Cells
Pursuing an Unmet Need in the Treatment of AML - SENTI-202 is designed to target and eliminate acute myeloid leukemia cells while sparing healthy bone marrow. Our vision is a potential medicine that does not rely on an invasive bone marrow transplant.
Product Details
Logic Gated Allogeneic CAR-NK Cell Therapy for AML
The unique product profile of SENTI-202 has the potential to drive towards a cure for AML without the need for a bone marrow transplant by enabling killing of diverse AML cells while sparing healthy stem cells that regenerate the blood and the immune systems.
Customer reviews
No reviews were found for Model SENTI-202 - Acute Myeloid Leukemia Cells. Be the first to review!